2-(4-(1,2-diphenylbutyl)phenoxy)-N,N-dimethylethan-1-amine | 6462-54-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-(4-(1,2-diphenylbutyl)phenoxy)-N,N-dimethylethan-1-amine
• 英文别名: 131I-TM-601；2-[4-(1,2-diphenylbutyl)phenoxy]-N,N-dimethylethanamine
• CAS: 6462-54-0
• 化学式: C₂₆H₃₁NO
• 分子量: 373.538
• InChiKey: YUFAHBUWIVNVNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  （E/Z）-他莫昔芬-d5 在 水 、 tert-butylammonium hexafluorophosphate(V) 、 甲烷 作用下， 以 乙腈 为溶剂， 以74 %的产率得到2-(4-(1,2-diphenylbutyl)phenoxy)-N,N-dimethylethan-1-amine
  参考文献：
  名称：

  用水电还原实现苄基烯烃的定点加氢/氘化

  摘要：

  苄基烯烃的电还原已应用于位点选择性氢化此类双键，同时存在在常规氢化条件下反应的其他功能。通过使用水作为质子源，该协议还允许通过简单地切换到 D 2 O 进行氘化。该方法的适用性通过使用商用电解装置和广泛的底物范围得到证明。

  DOI：

  10.1002/chem.202300849

文献信息

• MCCAGUE, RAYMOND;LECLERCQ, GUY, J. MED. CHEM., 30,(1987) N 10, 1761-1767
  作者：MCCAGUE, RAYMOND、LECLERCQ, GUY

  DOI：——

  日期：——
• FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
  申请人：Ramachandra Sumant

  公开号：US20110097340A1

  公开（公告）日：2011-04-28

  Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
• PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20200155521A1

  公开（公告）日：2020-05-21

  The present application is drawn to methods of treating a cell proliferative disorder, such as a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one of Compound 1, Compound 2, and Compound 3, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the cell proliferative disorder is treated.
• US8216571B2
  申请人：——

  公开号：US8216571B2

  公开（公告）日：2012-07-10
• [EN] FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING<br/>[FR] ANTICORPS ANTI-VEGF ENTIÈREMENT HUMAINS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2009055343A2

  公开（公告）日：2009-04-30

  Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.